Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBPNASDAQ:EDSANASDAQ:ERNANASDAQ:RWOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.30+4.6%$0.00$0.22▼$15.80$14.81M0.747.42 million shs108,986 shsEDSAEdesa Biotech$2.11+2.2%$2.05$1.55▼$5.59$14.78M0.39490,170 shs704 shsERNAErnexa Therapeutics$1.84+0.3%$2.79$1.75▼$39.38$13.52M5.3197,718 shs2,552 shsRWODRedwoods Acquisition$0.73$0.93$2.22▼$13.10$3.75MN/A108,185 shs22,784 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma-2.09%+6.28%-24.86%+28,589,900.00%+28,589,900.00%EDSAEdesa Biotech-3.29%+1.48%+12.57%-6.79%-52.06%ERNAErnexa Therapeutics-6.15%-0.54%-32.22%-28.90%-93.49%RWODRedwoods Acquisition0.00%0.00%0.00%0.00%-51.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AEDSAEdesa Biotech1.0528 of 5 stars2.03.00.00.00.61.70.6ERNAErnexa TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/AEDSAEdesa Biotech 4.00Strong Buy$5.00137.53% UpsideERNAErnexa Therapeutics 0.00N/AN/AN/ARWODRedwoods Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RWOD, EDSA, ASBP, and ERNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AERNAErnexa Therapeutics$535K25.26N/AN/A$0.50 per share3.67RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-508.70%N/AEDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)ERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-285.71%8/11/2025 (Estimated)RWODRedwoods AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RWOD, EDSA, ASBP, and ERNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.220.22EDSAEdesa BiotechN/A15.7215.72ERNAErnexa TherapeuticsN/A0.210.21RWODRedwoods AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%EDSAEdesa Biotech5.50%ERNAErnexa Therapeutics70.55%RWODRedwoods Acquisition20.07%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%EDSAEdesa Biotech22.60%ERNAErnexa Therapeutics1.50%RWODRedwoods Acquisition2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/AEDSAEdesa Biotech207.02 million5.44 millionNot OptionableERNAErnexa Therapeutics107.37 million7.03 millionNo DataRWODRedwoods AcquisitionN/A5.17 million5.06 millionNot OptionableRWOD, EDSA, ASBP, and ERNA HeadlinesRecent News About These CompaniesCal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public OfferingMay 23, 2025 | bakersfield.comBRedwood Holdings Limited vow to return Reading ‘to its rightful place in English football’ after completing takeoverMay 15, 2025 | nytimes.comRedwood Services Makes 19th AcquisitionMay 15, 2025 | achrnews.comARedwood Announces Investment by Atlas PartnersMay 9, 2025 | achrnews.comARedwood Materials preps for expansion spree with new R&D center in San FranciscoApril 2, 2025 | msn.comBlank-Check Company Cal Redwood Files for IPOMarch 4, 2025 | marketwatch.comEnvironmental Groups Praise Plan to Conserve Coastal Redwoods, Expand Protected LandFebruary 20, 2025 | sanjoseinside.comS$24 million land deal creates 7-mile-long Bay Area corridor of protected redwood forests to the oceanFebruary 12, 2025 | msn.comSave the Redwoods League signs $24 million deal to purchase Monte Rio redwood forest and expand county parkFebruary 12, 2025 | pressdemocrat.comP$24 million land deal creates 7-mile long corridor of protected redwood forests to the oceanFebruary 11, 2025 | eastbaytimes.comERedwood Gospel Mission finalizes purchase of former SAY Dream Center in Santa RosaJanuary 5, 2025 | pressdemocrat.comPRedwood Empire Whiskey Acquires Luxury Northern California DistilleryDecember 21, 2024 | markets.businessinsider.comAcacia Capital buys Redwood City apartments for $184MNovember 13, 2024 | therealdeal.comTRedwood Realty Negotiates $6.6M Sale of Jersey City Apartment BuildingOctober 24, 2024 | rebusinessonline.comRSave the Redwoods League acquires 750 acres of Redwood Forest in Sonoma and Mendocino Counties for future parks expansionsOctober 13, 2024 | ukiahdailyjournal.comUOne of California's most popular old-growth redwood parks is about to get biggerOctober 11, 2024 | msn.comSave the Redwood League acquires 750 acres of land to expand Montgomery Woods, Armstrong WoodsOctober 11, 2024 | mendovoice.comMRedwood Gospel Mission in line to buy former SAY Dream Center campus in Santa RosaOctober 6, 2024 | pressdemocrat.comPBMW of North America partners with Redwood MaterialsSeptember 27, 2024 | recyclingtoday.comRThree miles of scenic Northern California coastline preserved in major redwoods dealSeptember 12, 2024 | times-standard.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRWOD, EDSA, ASBP, and ERNA Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.30 +0.01 (+4.58%) As of 09:53 AM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Edesa Biotech NASDAQ:EDSA$2.10 +0.05 (+2.18%) As of 10:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Ernexa Therapeutics NASDAQ:ERNA$1.84 +0.01 (+0.27%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Redwoods Acquisition NASDAQ:RWODRedwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
